Report by Panmure Liberum SAM

Their Systematic Analysis Model (SAM) ranks 290 UK stocks by combining revisions momentum, shareholder value and valuation to identify the most attractive opportunities. Hikma Pharmaceuticals and SigmaRoc are the latest additions to their top 20 ideas. HIK screens as unusually cheap for its quality, ranking in the top quintile on capital-returns valuation and trading at just under 8.5x FY2 P/E. ROCE has been improving since 2022, revisions momentum has strengthened for 8 months and is back above median, while a new CFO and strategic reset provide meaningful recovery potential. SRC has seen ROCE grind higher with OPAT margins increasing materially following the successful integration of CRH assets. It is still very cheap with the market implying it can only do 6% ROCE with the FY2 forecast at 8%. Revisions Momentum is back above median and improved significantly over the past 3 months. There is also scope for further M&A. TPs are 1900p for HIK and 216p for SRC.

Report by Willis Welby

Methodology - the initial universe are stocks with $2bn+ M/Cap. After that Willis Welby starts with a quality cut off based on their measure of Intrinsic Return on Capital Employed. They then narrow down using a combination of share price momentum and EBIT revisions before incorporating their expectations analysis via their measure of the implied to Y3 EBITM ratio. This has been another month of low turnover for the UK screen and it is notable that stocks coming in are exclusively in Consumer Services with the return of three retailers (B&M, Pets at Home, WH Smith) and Flutter. The four stocks leaving are Burberry, IAG, Hikma and Serco.